IWLD
🇦🇺 ASX
NULL GLOBAL
NULL BETA
👑 Overview
📈 Performance
📙 Holdings
💰 Distributions
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💰
1.36%
Annual distribution yield
Based on the most recent distribution
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
90
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
IWLD.AX was created on 2016-04-22 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global, developed market large, mid and smallcapitalisation companies
📈 Performance
Price History
+76.16%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show more
NOVO NORDISK CLASS B
1.04%
Updated as of 26 September 2022
Industry Exposure
🤖 Information
31%
🩺 Health
13%
🏦 Financials
12%
🏭 Industrials
10%
📙 Other
10%
🛍️ Consumer
10%
📞 Communication
5%
🧱 Materials
4%
🏡 Real Estate
2%
⚡️ Utilities
2%
🔋 Energy
1%
Country Exposure
🇺🇸 United States of America (the)
70%
🇯🇵 Japan
6%
🇬🇧 United Kingdom of Great Britain and Northern Ireland (the)
5%
🇨🇦 Canada
3%
🇫🇷 France
3%
🇳🇱 Netherlands (the)
2%
🇨🇭 Switzerland
2%
🇩🇪 Germany
2%
🇩🇰 Denmark
1%
🇮🇪 Ireland
1%
🇸🇪 Sweden
1%
🇭🇰 Hong Kong
1%
Other
1%
💰 Distributions
Payouts
💰 Annual Distribution Yield*
1.36%
💰 Annual Distribution Earnings Per $1,000 invested**
$13.62
💰 Most Recent Distribution Franked Percentage Estimate
0.00%
💰 Average Distribution Franked Percentage Estimate
0.00 %
💰 Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.37
0.00%
2021
$6.41
0.00%
2020
$0.88
0.00%
2019
$0.89
0.00%
2018
$0.78
0.00%
2017
$0.45
0.00%
2016
$0.22
0.00%
💵 Costs
💼
0.09%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$44.92
💰 Price To Earnings Ratio
0.00
💰 Price To Book Ratio
0.00
💰 Leveraged
No
💰 Inverse
No
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IWLD
90
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IWLD
676 days
IWLD investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
22%
50k - 100k
46%
Less than 50k
24%
👶 Age of investors
18 - 25
9%
26 - 34
33%
35 - 90
58%
🙋 Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in IWLD also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
📊 Share price
$120.79 AUD
NULL AUSTRALIA
NULL BETA
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
Want more shares? Try these...
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. The company has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The firm is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.
📊 Share price
